Last reviewed · How we verify
Lasix (furosemide)
At a glance
| Generic name | furosemide |
|---|---|
| Also known as | Lasix, Frusemide |
| Sponsor | Generic (originally Hoechst AG) |
| Drug class | Loop Diuretic [EPC] |
| Target | ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1966-07-01 (United States) |
Approved indications
- Acute pulmonary edema
- Decompensated cardiac failure
- Edema
- Edema due to Hepatic Cirrhosis
- Hypertensive disorder
- Peripheral Edema due to Chronic Heart Failure
- Pulmonary Edema due to Chronic Heart Failure
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Cramping
- Oral and gastric irritation
- Anorexia
- Dizziness
- Headache
- Blurred vision
- Xanthopsia
- Orthostatic hypotension
Serious adverse events
- Severe anaphylactic or anaphylactoid reactions with shock
- Toxic epidermal necrolysis
- Stevens-Johnson syndrome
- Hepatic encephalopathy
- Pancreatitis
- Jaundice (intrahepatic cholestatic)
- Systemic vasculitis
- Necrotizing angiitis
- Aplastic anemia
- Agranulocytosis
Key clinical trials
- Use of Diuretics in Maintenance Hemodialysis Patients With Residual Renal Function Undergoing Bioimpedance-guided Fluid Management (NA)
- Weaning of Mechanical Ventilation Guided by the Natriuretic Peptide of Type B (Phase 3)
- Clinical Observation of Mean Systemic Filling Pressure in Critical Care Patients With Continuous Diuretics Administration (N/A)
- Central Sodium Sensing: Implications for Blood Pressure Regulation (NA)
- The Effect of Different Doses of Metformin or Furosemide on Rosuvastatin Pharmacokinetics Following Oral Administration in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Six-way Crosso (Phase 1)
- Non-invasive Fluid Management in Critically Ill Patients With ARDS (NA)
- Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure (AVOID-HF) (NA)
- Comparison of Diuretic Effect With Furosemide Alone Versus the Combination of Furosemide and Albumin in Cirrhotic Patients (Phase 4)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 11433044 | 2034-04-03 | Method of Use |
| 9884039 | 2034-04-03 | Method of Use |
| 12370168 | 2034-04-03 | Formulation |
| 10272064 | 2034-04-03 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |